A. Davis
Direttore/Membro del Consiglio presso ACASTI PHARMA INC.
Patrimonio netto: - $ in data 30/04/2024
Posizioni attive di A. Davis
Società | Posizione | Inizio | Fine |
---|---|---|---|
ACASTI PHARMA INC. | Direttore/Membro del Consiglio | 10/10/2023 | - |
Cortendo AB
Cortendo AB Miscellaneous Commercial ServicesCommercial Services Cortendo AB engages in the provision of biopharmaceutical business. Its activities include development and distribution of orphan drugs for metabolic and endocrine diseases as well as diabetes. Its products include cortisol inhibition and normocort. The company was founded on October 6, 1996 and is headquartered in Trevose, PA. | Direttore Finanziario/CFO | 23/03/2015 | - |
Contatto Relazioni con gli Investitori | 23/03/2015 | - | |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Direttore Finanziario/CFO | - | - |
Storia della carriera di A. Davis
Precedenti posizioni note di A. Davis
Società | Posizione | Inizio | Fine |
---|---|---|---|
VERRICA PHARMACEUTICALS INC. | Comptroller/Controller/Auditor | - | 16/07/2021 |
Direttore Finanziario/CFO | 07/10/2019 | 16/07/2021 | |
Contatto Relazioni con gli Investitori | - | 16/07/2021 | |
STRONGBRIDGE BIOPHARMA | Comptroller/Controller/Auditor | 26/05/2015 | 03/09/2019 |
Direttore Finanziario/CFO | 26/05/2015 | 03/09/2019 | |
TENGION, INC. | Direttore Finanziario/CFO | 03/08/2010 | 31/12/2014 |
Contatto Relazioni con gli Investitori | 01/07/2011 | 31/12/2014 | |
Segretario Aziendale | 01/08/2010 | 31/12/2014 | |
Treasurer | 04/08/2010 | 04/08/2010 | |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Direttore Finanziario/CFO | 01/01/1994 | 08/07/2010 |
MICRO Healthsystems, Inc.
MICRO Healthsystems, Inc. Packaged SoftwareTechnology Services MICRO Healthsystems, Inc. develops operating systems computer software. The private company is based in West Orange, NJ and has subsidiaries in the United States. | Comptroller/Controller/Auditor | 01/01/1991 | 01/01/1994 |
Formazione di A. Davis
The College of New Jersey | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 11 |
Posizioni
Director of Finance/CFO | 6 |
Comptroller/Controller/Auditor | 3 |
Investor Relations Contact | 3 |
Settori
Health Technology | 7 |
Consumer Services | 3 |
Technology Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
TENGION, INC. | Health Technology |
VERRICA PHARMACEUTICALS INC. | Health Technology |
ACASTI PHARMA INC. | Health Technology |
Aziende private | 5 |
---|---|
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
MICRO Healthsystems, Inc.
MICRO Healthsystems, Inc. Packaged SoftwareTechnology Services MICRO Healthsystems, Inc. develops operating systems computer software. The private company is based in West Orange, NJ and has subsidiaries in the United States. | Technology Services |
Cortendo AB
Cortendo AB Miscellaneous Commercial ServicesCommercial Services Cortendo AB engages in the provision of biopharmaceutical business. Its activities include development and distribution of orphan drugs for metabolic and endocrine diseases as well as diabetes. Its products include cortisol inhibition and normocort. The company was founded on October 6, 1996 and is headquartered in Trevose, PA. | Commercial Services |
Strongbridge Biopharma Plc
Strongbridge Biopharma Plc Pharmaceuticals: MajorHealth Technology Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA. | Health Technology |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
- Borsa valori
- Insiders
- A. Davis
- Esperienza